Abstract
Renal cell carcinoma accounts for 3% of all solid tumors and currently causes about 3,500 deaths/year in the UK. Once an orphan disease, it has undergone an impressive change in its natural history with an improvement in overall survival, thanks to the development of new target agents. In its management, renal cell carcinoma has been treated with both surgical and medical approaches. Nowadays, many more drugs are available, especially in the metastatic setting, so that we should reconsider the peculiar role of surgery and its interaction with target agents. Cytoreductive nephrectomy still plays a major role in the management of the disease, though no really solid data have been still obtained. Adjuvant and neoadjuvant settings, instead, are still under evaluation, especially new adjuvant therapies involving the numerous target agents we have. Finally, metastasectomy has a controversial role, with some evidence of more efficacy than the medical treatment, though it shows too many biases to be considered certain. The picture that comes out suggests a complex frame, in which we have great power to act, but in which we need to better comprehend the interactions that could be created between surgery and medical therapies, to achieve an optimal multimodal treatment for renal cell carcinoma.
| Original language | English |
|---|---|
| Pages (from-to) | 9-15 |
| Number of pages | 7 |
| Journal | Urologia |
| Volume | 78 Suppl 18 |
| DOIs | |
| Publication status | Published - Oct 2011 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Surgery and target agents for renal cell carcinoma treatment : the path between proper interaction. / Ganini, Carlo; Rovereto, Bruno; Porta, Camillo.
In: Urologia, Vol. 78 Suppl 18, 10.2011, p. 9-15.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Surgery and target agents for renal cell carcinoma treatment
T2 - the path between proper interaction.
AU - Ganini, Carlo
AU - Rovereto, Bruno
AU - Porta, Camillo
PY - 2011/10
Y1 - 2011/10
N2 - Renal cell carcinoma accounts for 3% of all solid tumors and currently causes about 3,500 deaths/year in the UK. Once an orphan disease, it has undergone an impressive change in its natural history with an improvement in overall survival, thanks to the development of new target agents. In its management, renal cell carcinoma has been treated with both surgical and medical approaches. Nowadays, many more drugs are available, especially in the metastatic setting, so that we should reconsider the peculiar role of surgery and its interaction with target agents. Cytoreductive nephrectomy still plays a major role in the management of the disease, though no really solid data have been still obtained. Adjuvant and neoadjuvant settings, instead, are still under evaluation, especially new adjuvant therapies involving the numerous target agents we have. Finally, metastasectomy has a controversial role, with some evidence of more efficacy than the medical treatment, though it shows too many biases to be considered certain. The picture that comes out suggests a complex frame, in which we have great power to act, but in which we need to better comprehend the interactions that could be created between surgery and medical therapies, to achieve an optimal multimodal treatment for renal cell carcinoma.
AB - Renal cell carcinoma accounts for 3% of all solid tumors and currently causes about 3,500 deaths/year in the UK. Once an orphan disease, it has undergone an impressive change in its natural history with an improvement in overall survival, thanks to the development of new target agents. In its management, renal cell carcinoma has been treated with both surgical and medical approaches. Nowadays, many more drugs are available, especially in the metastatic setting, so that we should reconsider the peculiar role of surgery and its interaction with target agents. Cytoreductive nephrectomy still plays a major role in the management of the disease, though no really solid data have been still obtained. Adjuvant and neoadjuvant settings, instead, are still under evaluation, especially new adjuvant therapies involving the numerous target agents we have. Finally, metastasectomy has a controversial role, with some evidence of more efficacy than the medical treatment, though it shows too many biases to be considered certain. The picture that comes out suggests a complex frame, in which we have great power to act, but in which we need to better comprehend the interactions that could be created between surgery and medical therapies, to achieve an optimal multimodal treatment for renal cell carcinoma.
UR - http://www.scopus.com/inward/record.url?scp=84856267163&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84856267163&partnerID=8YFLogxK
U2 - 10.5301/RU.2011.8769
DO - 10.5301/RU.2011.8769
M3 - Article
C2 - 22081423
AN - SCOPUS:84856267163
VL - 78 Suppl 18
SP - 9
EP - 15
JO - Urologia
JF - Urologia
SN - 0391-5603
ER -